Pharmacokinetic Effects of Antidrug Antibodies Occurring in Healthy Subjects After a Single Dose of Intravenous Infliximab
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-6901
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Pharmacokinetic Effects of Antidrug Antibodies Occurring in Healthy Subjects After a Single Dose of Intravenous Infliximab ; day:6 ; month:9 ; year:2017 ; pages:1-7
Drugs in R & D ; (6.9.2017), 1-7
- Keyword
-
Biopharmazie
Pharmakodynamik
Pharmakokinetik
- Creator
-
Ehrenpreis, Eli D.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40268-017-0211-y
- URN
-
urn:nbn:de:1111-2017111114064
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:36 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ehrenpreis, Eli D.
- SpringerLink (Online service)
Other Objects (12)
Pharmacokinetic Evaluation of Intravenous Vitamin C: A Classic Pharmacokinetic Study
Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab
Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study
Pharmacokinetic disposition of erythraline in rats after intravenous administration
Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study
The Effectiveness of Intravenous Golimumab Administered Directly After Infliximab in Rheumatoid Arthritis Patients
Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
Pharmacokinetic modeling of intravenous sildenafil in newborns with congenital diaphragmatic hernia
A whole-body mechanistic physiologically-based pharmacokinetic modeling of intravenous iron
Antifungal antibodies present in intravenous immunoglobulin derived from China
Pharmacokinetic Evaluation of Intravenous Vitamin C: A Classic Pharmacokinetic Study
Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab
Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study
Pharmacokinetic disposition of erythraline in rats after intravenous administration
Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study
The Effectiveness of Intravenous Golimumab Administered Directly After Infliximab in Rheumatoid Arthritis Patients
Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
Pharmacokinetic modeling of intravenous sildenafil in newborns with congenital diaphragmatic hernia
A whole-body mechanistic physiologically-based pharmacokinetic modeling of intravenous iron
Antifungal antibodies present in intravenous immunoglobulin derived from China
Pharmacokinetic Evaluation of Intravenous Vitamin C: A Classic Pharmacokinetic Study
Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab
Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study
Pharmacokinetic disposition of erythraline in rats after intravenous administration
Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study
The Effectiveness of Intravenous Golimumab Administered Directly After Infliximab in Rheumatoid Arthritis Patients
Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
Pharmacokinetic modeling of intravenous sildenafil in newborns with congenital diaphragmatic hernia
A whole-body mechanistic physiologically-based pharmacokinetic modeling of intravenous iron